We are a team of passionate scientists, doctors and clinicians, driven to fight late stage cancers.
About our company, our mission and our team.
Overview of our pipeline and our science
Latest news releases and investor packages
Our pipeline consists of a promising family of small molecules inhibitors of proteins responsible for unconstrained proliferation signaling and metastasis.
Pancreatic Ductal Adenocarcinoma
ANV221 is novel product candidate shown to reduce pancreatic cancer tumor size and suppress metastases superior to approved standard of care drugs in vivo models.
Triple-Negative & HER2+ Breast Cancers
ANV221 halts tumor growth equivalent to standard of care chemotherapies in triple-negative and Her2+ breast cancers in vivo models with potential reversal of drug resistance in HER2+ breast, gastric, and cervical cancers
